Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells

Molecular Vision

Volumn 17, Issue , 2011, Pages 3339-3346

  Rusovici, Raluca ^a   Sakhalkar, Monali ^a   Chalam, Kakarla V ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LIPOCORTIN 5; PROPIDIUM IODIDE; TETRAZOLIUM; TRYPAN BLUE; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; BRIGHT FIELD MICROSCOPY; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA ENDOTHELIUM; COW; CYTOTOXICITY; DRUG RESPONSE; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; STAINING; TOXICITY TESTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANNEXIN A5; ANTERIOR CHAMBER; ANTIBODIES, MONOCLONAL, HUMANIZED; CATTLE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CORNEA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GLAUCOMA, NEOVASCULAR; HUMANS; MICROSCOPY; NEOVASCULARIZATION, PATHOLOGIC; TRYPAN BLUE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856146884     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. CATT Research Group. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med 2011; 364:1897-908. [PMID: 21526923]
2. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal Bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007; 27:432-8. [PMID: 17420694]
3. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal Bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007; 27:419-25. [PMID: 17420692]
4. Saxena S, Kishore P, Pandey S, Khattri M, Kumar D. Topical Bevacizumab for corneal neovascularization after penetrating keratoplasty. Eur J Ophthalmol 2009; 19:870-2. [PMID: 19787612]
5. Zarnowski T, Tulidowicz-Bielak M. Topical Bevacizumab is efficacious in the early bleb failure after trabeculectomy. Acta Ophthalmol 2011; 89:e605-6. [PMID: 19925517]
6. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Short-and long-term safety profile and efficacy of topical Bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247:1375-82. [PMID: 19415316]
7. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal Bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007; 23:487-91. [PMID: 17900231]
8. Chalam KV, Gupta SK, Grover S, Brar VS, Agarwal S. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol 2008; 18:255-62. [PMID: 18320519]
9. Yoeruek E, Spitzer MS, Tatar O, Biedermann T, Grisanti S, Lüke M, Bartz-Schmidt KU, Szurman P. Toxic effects of recombinant tissue plasminogen activator on cultured human corneal endothelial cells. Invest Ophthalmol Vis Sci 2008; 49:1392-7. [PMID: 18385055]
10. Crissman HA, Steinkamp JA. Rapid, simultaneous measurement of DNA, protein, and cell volume in single cells from large mammalian cell populations. J Cell Biol 1973; 59:766-71. [PMID: 4128323]
11. Chalam KV, Agarwal S, Brar VS, Murthy RK, Sharma RK. Evaluation of cytotoxic effects of Bevacizumab on human corneal cells. Cornea 2009; 28:328-33. [PMID: 19387236]
12. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009; 54:372-400. [PMID: 19422965]
13. Murphy C, Alvarado J, Juster R, Maglio M. Prenatal and postnatal cellularity of the human corneal endothelium. A quantitative histologic study. Invest Ophthalmol Vis Sci 1984; 25:312-22. [PMID: 6698749]
14. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P, Tübingen Bevacizumab Study Group. Safety, penetration and efficacy of topically applied Bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 2008; 86:322-8. [PMID: 17995975]
15. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000; 41:2514-22. [PMID: 10937562]
16. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, Pavan-Langston D, Dana R. Topical Bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127:381-9. [PMID: 19365012]
17. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group. Intracameral Bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142:158-60. [PMID: 16815268]
18. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of Bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142:155-8. [PMID: 16815267]
19. Bayar SA, Altinors DD, Kucukerdonmez C, Akova YA. Severe corneal changes following intravitreal injection of Bevacizumab. Ocul Immunol Inflamm 2010; 18:268-74. [PMID: 20662658]
20. Yoeruek E, Tatar O, Spitzer MS, Saygili O, Biedermann T, Bartz-Schmidt KU, Thaler S, Szurman P. Effects of Bevacizumab on apoptosis, Na+-K+-adenosine triphosphatase and zonula occludens 1 expression on cultured corneal endothelial cells. Ophthalmic Res 2010; 44:43-9. [PMID: 20173357]
21. Hosny MH, Zayed MA, Shalaby AM, Eissa IM. Effect of intracameral Bevacizumab injection on corneal endothelial cells: an in vivo evaluation. J Ocul Pharmacol Ther 2009; 25:513-7. [PMID: 19929596]
22. de Moraes CG, Facio AC, Costa JH, Malta RF. Intracameral Bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series. J Ocul Biol Dis Infor 2009; 2:40-6. [PMID: 20072647]
23. Park HY, Kim SJ, Lee HB, Kim ES, Tchah H. Effect of intracameral bevacizumab injection on corneal endothelium in rabbits. Cornea 2008; 27:1151-5. [PMID: 19034131]
24. Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral Bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 2009; 93:273-4. [PMID: 18617542]
25. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of Bevacizumab on cultured human corneal cells. Cornea 2007; 26:977-82. [PMID: 17721300]
26. Shin JP, Lee JW, Sohn BJ, Kim HK, Kim SY. In vivo corneal endothelial safety of intracameral Bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation. J Glaucoma 2009; 18:589-94. [PMID: 19826387]